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Abstract
Genetic screening is becoming possible on an unprecedented scale. However, its utility remains controversial. Although
most variant genotypes cannot be easily interpreted, many individuals nevertheless attempt to interpret their genetic
information. Initiatives such as the Personal Genome Project (PGP) and Illumina’s Understand Your Genome are sequencing
thousands of adults, collecting phenotypic information and developing computational pipelines to identify the most
important variant genotypes harbored by each individual. These pipelines consider database and allele frequency
annotations and bioinformatics classifications. We propose that the next step will be to integrate these different sources of
information to estimate the probability that a given individual has specific phenotypes of clinical interest. To this end, we
have designed a Bayesian probabilistic model to predict the probability of dichotomous phenotypes. When applied to a
cohort from PGP, predictions of Gilbert syndrome, Graves’ disease, non-Hodgkin lymphoma, and various blood groups were
accurate, as individuals manifesting the phenotype in question exhibited the highest, or among the highest, predicted
probabilities. Thirty-eight PGP phenotypes (26%) were predicted with area-under-the-ROC curve (AUC).0.7, and 23 (15.8%)
of these were statistically significant, based on permutation tests. Moreover, in a Critical Assessment of Genome
Interpretation (CAGI) blinded prediction experiment, the models were used to match 77 PGP genomes to phenotypic
profiles, generating the most accurate prediction of 16 submissions, according to an independent assessor. Although the
models are currently insufficiently accurate for diagnostic utility, we expect their performance to improve with growth of
publicly available genomics data and model refinement by domain experts.
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Introduction
A central question in modern human genetics is how inter-
individual variation impacts human phenotypes. Unprecedented
technological advances will soon make whole genome DNA
sequencing services available to a large number of people.
However, interpreting the variant genotypes found in an
individual’s genome remains challenging, and is the focus of
many academic, government, and commercial efforts. Here we
address some limitations of state-of-the-art biomedical informatics
tools to interpret genomic data, and we propose a Bayesian
probabilistic model that begins to address these limitations.
An individual’s whole genome sequence yields 3.2 million
variant genotypes on average [1]. Genome interpretation requires
reducing this very large number to a more tractable list. Current
informatics tools prioritize variant genotypes, using database
annotations, bioinformatics function prediction, and allele fre-
quencies. For example, the PGP’s GET-Evidence pipeline [1]
prioritizes non-synonymous substitution variant calls over other
alterations and ranks variant calls with a heuristic point system
incorporating PolyPhen-2 classifications [2], and variant allele
frequencies, variant and gene annotations in multiple public
databases. The ‘‘Disease Risk of Volunteers Project’’ informatics
pipeline identifies disease-causing mutations (DMs) in the Human
Gene Mutation Database [3], eliminates any variants with minor
allele frequency (MAF).0.01, those predicted to be benign by two
out of three bioinformatics classifiers, and those seen more than
three times in their cohort. In both projects, short lists of putatively
important risk variant genotypes identified by the pipelines are
reviewed by researchers and shared with participants.
However, the purpose of personal genome interpretation is to
understand how variant genotypes impact upon an individual’s
lifetime risk of specific diseases or traits. Annotating single variant
genotypes is just the first step. Most human phenotypes result from
a constellation of variant genotypes and non-genetic contributions.
Here we shift the focus from interpretation of single variant
genotypes to identifying genes and genotypes that impact the
phenotype and estimating their penetrance. To our knowledge,
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the only previous comparable approach to this problem consid-
ered each variant genotype as an independent medical test with an
associated likelihood ratio [4]. A ‘‘pre-test’’ probability of
phenotype, based on age- and gender-based prevalence, was
multiplied by a chain of likelihood ratios for each common variant,
yielding a post-test probability of phenotype. In a pioneering study
of the genome of a single individual, this method was used to
predict the probability of 55 disease phenotypes [5]. The
likelihood ratios were derived from extensive database annotations
and 480 publications of cohort and case-control studies.
We present a formal Bayesian probabilistic model that for the
first time integrates annotations of phenotype prevalence, both
rare and common variant genotypes and disease-associated genes,
and yields a single posterior probability for a phenotype of interest.
We use self-reported phenotypes and medical information shared
by participants in the PGP to quantitatively assess the performance
of the model on a cohort of individuals. Notably, our models do
not use information from the 130 members of the PGP cohort to
fit or optimize parameters. However, eventually the availability of
information from thousands of individuals could enable learning
these parameters directly from individuals’ genomes and reported
phenotypes, enabling significantly better phenotype predictions.
Results
For each phenotype, we used our model to compute the
posterior probability of each individual having that phenotype
(Text S1: Eq 3) and ranked the 130 PGP participants accordingly.
The individual with the largest posterior probability was assigned
Rank #1, the second largest Rank #2, and so forth. Then we
assessed the ranking for each phenotype using area under the
ROC curve (AUC) and computed the statistical significance of the
AUC according to nominal p-value and false discovery rate (FDR)
(Methods). Thirty-eight PGP phenotypes (26%) were predicted
with area-under-the-ROC curve (AUC).0.7, and 23 (15.8%) of
these were statistically significant (p-value,0.05 and FDR,0.1)
(Figure 1). Sixty-four phenotypes were predicted as random or
worse (AUC#0.5). Our statistics are based on the assumption that
there is correlation structure among the phenotypes, which
provides a small benefit to the number of significant predictions
and expected FDR. If the phenotypes were truly uncorrelated, 21
predictions would be significant (p-value,0.05 and FDR,0.2)
(Table S12).
The model incorporated both genome sequence and population
phenotype prevalence, and we measured the contributions of each
to prediction performance. First, AUC, p-values and FDR for the
top predicted 38 phenotypes were computed using each
individual’s estimated phenotype prevalence instead of a
posterior probability. Next, we repeated these computations
using the genome sequences and assigning each phenotype the
same baseline prevalence, set to be the average prevalence
across all phenotypes. Comparison of genome-only, prevalence-
only, and combined results showed that 14 phenotypes had
higher genome-only than prevalence-only AUCs (Figure 2).
Thus, these phenotypes likely have a strong genetic component,
and at least some of the underlying genes and variant genotypes
are represented in the annotation databases. Finally, we
explored whether all categories of genomic annotations –
GWAS hits, variant genotypes in disease-associated genes, and
high-penetrance variant genotypes – were useful in predicting
each phenotype, by calculating the prediction performance if
only one of these had been used.
Six of the phenotypes were predicted best by GWAS hits – the
autoimmune disorders Graves’ disease, alopecia areata and
Crohn’s disease; the cardiovascular disorders, deep vein throm-
bosis and aortic aneurism; and chronic obstructive pulmonary
disease (Figure 3). Only one PGP participant (PGP-48) had
Graves’ disease, and she was ranked second out of 130
(AUC=1.0) (Figure 1). Her genome harbored numerous risk
alleles at the sites of 16 GWAS hits (9 homozygous and 7
heterozygous risk alleles). One PGP participant (PGP-69) had
alopecia areata (autoimmune-related hair loss), and he was ranked
seventh out of 130 (AUC=0.953). His genome harbored 7 GWAS
hits (4 homozygous and 3 heterozygous risk alleles). A complete list
of PGP participants with these six phenotypes and the underlying
GWAS hits are in Tables S1, S2, S3, S4, S5, S6.
Three phenotypes were predicted best by non-synonymous
coding variants in annotated disease genes and bioinformatics
variant classifications – the common, hereditary liver disease
Gilbert’s syndrome, epilepsy and non-age-related cataracts (Fig-
ure 3). Only one of these predictions was statistically significant
(Gilbert’s syndrome, P= 0.023 and FDR=0.073) (Figure 1). One
PGP participant (PGP-125) reported having Gilbert’s syndrome,
and he was ranked third out of 130 (AUC=0.984). He had a rare,
heterozygous missense mutation P229L in the Gilbert’s syndrome-
associated gene UGT1A1. Of note, with only 130 samples, if only
one PGP participant had a particular phenotype, statistical
significance according to our permutation test required that the
model allocate them rank 1–4 within the cohort.
Five phenotypes were predicted best by high penetrance variant
genotypes – von Willebrand disease, hypertrophic cardiomyopa-
thy, and three blood groups (Figure 3). Only the blood groups
were statistically significant (Figure 1). The A, B and O blood
groups were well represented in the 130 PGP participants, and
known variant genotypes [6] ranked individuals with AUC=0.92
for group A, AUC=1 for group B, and AUC=0.917 for group O.
In addition, 27 phenotypes had combined results – genome
sequence plus prevalence – better than or equal to prevalence-only
AUC (Figure 2, Table S7).
With a few exceptions (blood groups and Gilbert’s syndrome),
all of our best-predicted phenotypes were complex and multi-
genic. Common variants, likely involved in transcriptional
regulation, and rare variants causing protein defects, both played
important roles in these predictions. However, for each phenotype,
the best predictions were generated by only a single category of
annotations and were either GWAS hits, high penetrance variants,
low penetrance genes containing rare variants, or high penetrance
genes containing rare variants.
Of all the best-predicted phenotypes, only glaucoma benefited
from more than one category of annotations – high penetrance
Author Summary
The Personal Genome Project (PGP) is an emerging
community whose goal is to collect and publicly share
genomes, environmental data, medical records, and
clinical traits from tens of thousands of volunteers. This
information may enable computer software to establish
the relationships between patterns of alterations in human
genomes and clinical phenotypic traits. We describe a
novel, Bayesian mathematical model to predict such traits
from genome sequence and population prevalence. The
core of the model is a set of phenotypic penetrance
estimates for aggregated genetic variants, which are
learned without any information about particular individ-
uals in a cohort of interest. We illustrate the model’s utility
in ranking individuals in the PGP cohort, according to their
probability of having 146 phenotypes.
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variants and low penetrance genes. For this phenotype, the two
PGP participants with glaucoma (PGP-15 and PGP-88) were
ranked as 6 and 17 out of 130 (AUC=0.92) (Figure 1). PGP-15
had a glaucoma-associated high-penetrance variant in the gene
WDR36 (A449T), and PGP-88 had a rare variant (N286T) in the
glaucoma-associated gene PCMTD1.
Figure 1. Prediction results of the model on 38 dichotomous phenotypes. Each row represents a clinical phenotype and consists of 130
cells, each of which represents a Personal Genome Project (PGP) participant. Cells in each row are ranked by the posterior probability that the
participant has the phenotype. Cells are colored by true phenotypic status. Blue cells indicate that a participant has the phenotype, and red cells that
a participant does not have the phenotype. If a cell is colored light grey, the true phenotypic status is unknown. If a cell is colored dark grey, the PGP
participant is not considered in the evaluation because the phenotype is gender-specific. #PGP=number of participants in each row having the true
phenotypic status. AUC= area under the receiver operating characteristic curve, a threshold-free metric of classifier performance. p-value and
FDR= statistical significance of the AUC value, based on permutation testing.
doi:10.1371/journal.pcbi.1003825.g001
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In 2012–13, the Critical Assessment of Genome Interpretation
(CAGI) blinded prediction experiment included a challenge based
on prediction of PGP phenotypes. A total of 291 PGP participants
provided phenotypic profiles, reporting their status with respect to
243 dichotomous clinical traits to the experiment organizers. We
were one of several prediction teams, who were provided both
genomic data for 77 PGP participants and 291 phenotypic
profiles, of which 214 were decoys. The challenge was to identify
Figure 2. Contribution of population prevalence and genome sequence to prediction results in Fig. 1. Each row represents a phenotype
and consists of three cells, representing (a) model predictions based only on phenotype-specific population prevalence (Prevalence Only), (b) model
predictions based on genome sequence (with assumption that every phenotype and every individual has the same prevalence), and (c) model
predictions that combine genome sequence and phenotype-specific population prevalence. Cells are colored by the area under the ROC curve (AUC)
yielded by each model. Contributions vary among phenotypes due to differences in quality of available information with respect to prevalence and
database annotations of variant genotypes.
doi:10.1371/journal.pcbi.1003825.g002
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the 77 PGP participants by matching their genomes and profiles.
We used the posterior probabilities of our phenotypic models to
provide a rank order matching of the PGP participants and their
profiles. Briefly, for each participant, the phenotypic profiles were
ranked from most probable to least probable for that individual.
Prediction teams were evaluated by an independent assessor based
on count of correct top-ranked profiles and also by mean rank of
the correct profiles for all participants.
For 27 of the 77 PGP participants, genotypic data from
23andMe was also available to the prediction teams on the PGP
website, and identification of these participants was considered to
be trivial. Furthermore, the website contained the critical
Figure 3. Contribution of GWAS hits, low penetrance genes, high penetrance genes, and high penetrance variants to prediction
results. Each row represents a phenotype predicted with AUC.0.7 by genome sequence (Figure 2 (b)) and contains five cells. Cells are colored by
the area under the ROC curve (AUC) yielded by a model that contains only 1:GWAS hits, 2:Low penetrance genes, 3:High penetrance genes, 4:High
penetrance variants. The fifth cell shows AUC of the combination model used to assess results in this work that considers all of 1,2,3, and 4. The
combination model generally yields the best performance: however, for most phenotypes, only one or two of 1, 2, 3 or 4 appears to contribute.
doi:10.1371/journal.pcbi.1003825.g003
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information that no blood or saliva samples had been collected for
108 of the profile decoys, thereby making it possible to exclude
these profiles as potential matches. According to the independent
assessor, after elimination of the 27 participants with genotypic
data and the 108 profile decoys, our team correctly predicted the
largest number (six) of top-ranked participants and had the lowest
mean rank for correct profiles (25.4), of the 16 submissions to the
challenge. Based on an empirical null distribution, our prediction
had p-value,1024 (Methods).
Discussion
We introduce a Bayesian probabilistic model that allows
individuals to estimate their risk of having a dichotomous
phenotype. The models could be useful as an extension to existing
pipelines for genome interpretation, such as those currently used
by PGP (GET-Evidence) [1], DRV [7], UYG, and the Inter-
pretome [8]. These pipelines rely on database annotations of
variant genotypes and genes, allele frequencies and bioinformatics
methods for variant function prediction. The PGP, DRV, and
UYG pipelines yield lists of prioritized variant genotypes and
associated evidence to support the hypothesis as to whether a
single variant genotype is involved in a given disease/trait of
interest. The Interpretome provides prioritized lists for rare
variants and phenotype predictions based on common variants.
Our Bayesian probabilistic model could use any of these
prioritized lists and provide phenotype predictions, which consider
the contributions of both rare and common variants.
Strengths of our model
The model presented here could be used in the setting of an
adult volunteer cohort. Within this setting, it provides interpret-
able results to help individuals understand their risk of a phenotype
of interest. To our knowledge, it is the first such model to use
population-level prevalence as a prior, integrate the contribution
of rare and common variant genotypes harbored by an individual,
and consider the modulating effects of incomplete penetrance,
environmental, and unknown factors. In addition to a final
posterior estimate of an individual’s phenotypic risk, the model
provides information about the separate contributions of popula-
tion-level prevalence and personal genome sequence. Each
individual can also learn their rank probability within the cohort,
a number that may be easier to understand than a raw posterior
probability. We can further inform individuals as to how much
each prediction can be trusted, based on the model’s previous
performance.
The model is flexible, and it can be reasonably applied to
predict any individual’s probability of having any dichotomous
phenotype with a genetic component. The key elements are:
estimating prior probabilities that the individual has the pheno-
type, ideally considering age, gender and ancestry; identifying
annotated genes and variant genotypes associated with the
phenotype; finding the subset of those present in the individual’s
genome sequence and estimating their aggregate penetrance; and
finally computing the posterior probability that the individual has
the phenotype. Genes and variant genotypes are sorted into four
categories: low penetrance variants, low penetrance genes, high
penetrance variants, and high penetrance genes. The aggregate
penetrance of each category is estimated with a mathematical
model (Text S1: Eqs. 10–14). Bioinformatics variant function
predictions are also incorporated. Variant genotypes in all
phenotype-associated genes are scored with VEST [9], a
bioinformatics classifier that estimates a significance level (p-value)
for each variant score. The p-values are aggregated into a
gene-level score using Fisher’s method, then used to estimate the
posterior probability that the gene was affected, with empirical
data (Methods). Any variant function prediction method that
yields p-values and/or any of a number of gene-level variant
aggregation methods can be used.
The advantage of integrating the impact of both rare and
common variants can be quantified by comparing our model with
a model based only on the burden of putatively damaging alleles
(MAF,0.01) in our sets of phenotype-associated genes. When
applied to the same PGP cohort, this simple burden model yielded
only one predicted phenotype that was statistically significant after
multiple testing correction (in contrast to our model’s 23
statistically significant predicted phenotypes) (Figure S1).
Limitations of the current model
Incomplete and inaccurate information about genes, variant
genotypes, and phenotypes in current databases limit the model’s
utility. As an example, for 42 PGP phenotypes, we were unable to
find any associated genes or variants. Furthermore, the association
of a particular gene or variant to a phenotype may not be
quantitative, with respect to effect size. Thus, we make simplifying
quantitative assumptions about their aggregate penetrance, as
follows: 1) GWAS hits and any disease-gene associations lacking
careful curation are assigned low penetrance; 2) curated (DM)
disease variants and genes in HGMD and OMIM are assigned
high penetrance; 3) presence of a highly penetrant variant
dominates the posterior (Text S1: Eq 4); 4) penetrance of a
GWAS hit is estimated by its reported odds ratio, allele frequency
and phenotype prevalence (Text S1: Eqs. 21–25); 5) the effect sizes
of rare non-silent variants are assigned to be greater than the effect
sizes of GWAS hits associated with the same phenotype [10]; 6)
changes in gene product function are computed using only rare
(MAF,0.01) non-silent variants; 7) interactions among genes and
variant genotypes are not considered; 8) low prevalence is assigned
to variants and genes with high penetrance; 9) Only small-scale,
non-silent variants are considered, although some phenotypes may
be better predicted by other genetic or epigenetic alterations.
The phenotypes predicted in our study include those known to
have strong genetic components, such as Gilbert’s syndrome, von
Willebrand disease and epilepsy [11–13] and others lacking
evidence of strong genetic contribution, such as hiatal hernia and
dental cavities [14,15]. Of 146 phenotypes, we identified
associated genes or variant genotypes for 104. If we consider the
raw count of annotated genes, GWAS hits, and high penetrance
variants per phenotype, the range is large, with some phenotypes
having thousands and others fewer than ten annotations
(Figure 4). These differences affected our ability to predict
phenotypes. For example, Gilbert’s syndrome and von Willebrand
disease were among our best-predicted phenotypes. Both have
been studied for many years and causal genes (UGT1A1 for
Gilbert’s syndrome and VWF for von Willebrand disease) are
known [11,12]. By contrast, ulcerative colitis is believed to have a
genetic component but the causal genes are still largely unknown
[16], and no genetic components for dandruff have been identified
[17].
Out of seven cancer phenotypes, only kidney cancer and non-
Hodgkins lymphoma were predicted with AUC.0.7 and high
statistical significance (P-value,0.05, FDR,0.1), and these
predictions were driven by population-based priors (Figure 2).
Because most cancers have strong environmental contributions,
improved predictions would require more information about
carcinogen exposures and resulting patterns of somatic mutations.
Our current models rely on germline variants, which may be
A Probabilistic Model to Predict Clinical Traits from Genome Sequence
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useful for predicting familial cancers, but are less relevant for the
more common sporadic cancers.
Our model predictions for 64 PGP phenotypes were no better
than random (Table S8). For 38 phenotypes, either we were
unable to find evidence of phenotypic association with genes or
variant genotypes, or we found such evidence but were unable to
match it with variants in any PGP genomes. For the remaining 26
phenotypes, we suspect that errors in annotations and in our
model assumptions about penetrance are responsible. For
example, our predictions of hereditary neuropathies in PGP
(including Charcot-Marie-Tooth disease) yielded an AUC of
0.405. We identified 813 mutations in 37 genes associated with
this phenotype in HGMD’s high confidence of disease association
(DM) class. Although six of these were found in the genomes of
nine PGP participants, none of them reported this clinical
phenotype. It appears that in assuming that HGMD DM
mutations had high penetrance, we overestimated the probability
that these nine individuals had a hereditary neuropathy. In
addition, one PGP participant reported the phenotype but did
not have any of the mutations, which could be due to our
omission of the most common causes of hereditary neuropathy –
duplications or deletions of the PMP22 (peripheral myelin
protein) gene [18].
Future work
Improvements in the infrastructure of disease gene annotations
and the growing communities of adult volunteers, such as the
PGP, have the potential to significantly improve the utility of the
model proposed here. We have discussed the many simplifying
assumptions about penetrance parameters that were used in the
current work. However, if a resource that provided the genomes
and phenotypic profiles of a large number of people were
available, we could use it for maximum likelihood estimation of
the penetrance parameters in our model. Such a resource would
also allow us to generate reference panels for adult genetic testing.
We could use our model to compute the posterior probability of
each sequenced individual for each phenotype of interest and
generate ranked lists consisting of thousands of individuals. As the
lists grow larger, they would also grow in utility for individuals who
learn their ranking within the lists. The model could also be
extended to include genomic copy number variations and even
data from microbiomes.
We expect that as a larger number of individuals become
interested in personal genomics, members of communities such as
the PGP will have access to family pedigree information and/or
genotype or sequencing data from family members. The
availability of pedigree information would allow us to estimate a
Figure 4. Distribution of annotated genes, GWAS hits and high penetrance variants for phenotypes analyzed in this study.
Phenotypes are ordered by total counts of annotated genes and variants that we found. Counts are shown on a log scale for easier visualization. For
each phenotype the (log) count of annotated genes is colored red, GWAS hits green, and high penetrance variants blue. Some phenotypes have a
very large number of annotations and others have very few. For 42 phenotypes, we did not find any annotated genes or variants.
doi:10.1371/journal.pcbi.1003825.g004
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personalized phenotype prior for each individual, rather than
estimating these priors only by population prevalence. Numerous
methods have been developed for this purpose [19–21]. Genotype
or sequencing data from family members could be used to improve
both imputation of missing genotypes and phasing [22,23]. While
phasing is not currently considered in our models, knowledge of
whether multiple variants are in the same haplotype or simply on
the same chromosome could be informative with respect to their
phenotypic impact [24–26].
We are optimistic that integrated models such as the one
presented here will contribute to increasingly accurate and
interpretable predictions of clinical phenotype from genome
sequence in the near future.
Methods
PGP genomes
We downloaded variant genotypes from 174 genomes se-
quenced by Complete Genomics with the 2.0 Standard pipeline,
from the PGP website (http://my.pgp-hms.org) (as of 02/10/
2014). The PGP genomic data were obtained by sequencing DNA
purified from lymphocyte cell lines [1]. Variant genotypes were
obtained from the GFF format file produced by PGP’s Genome-
Environment-Trait-Evidence (GET-Evidence) pipeline [1]. Only
variant position, reference and alternative allele calls from the
GFF file were employed. 44 genomes were excluded from
consideration due to missing either a trait survey, associated age,
gender or ancestry, or did not have GET-Evidence GFF files,
yielding 130 genomes to be analyzed.
PGP-phenotypes
PGP participants have the option of filling out a ‘‘traits
questionnaire’’, consisting of 239 dichotomous phenotypes. Blood
groups were also provided in ‘‘Personal Health Records’’ of the
participants, yielding a total of 243 phenotypes. Results of the
questionnaire and blood groups were downloaded from the PGP
website and considered to be accurate. Of the 243 phenotypes,
only 153 were reported by at least one PGP participant, and 146
also had available prevalence information.
Phenotype prevalence and heritability
Internet searches for information about the prevalence and
heritability of each trait were performed manually. Wherever
possible, we found the most relevant prevalence for an individual,
considering her/his age, gender, and self-reported ancestry. Data
sources included SEER (NCI), websites for CDC (http://www.
cdc.gov) and HHS (http://www.hhs.gov/), and the published
literature. A complete list of sources and prevalence estimates is to
be found in Table S9. Scripts are available on request from the
authors.
Gene and variant annotations
Variant annotations were collected from NHGRI-GWAS
(https://www.genome.gov/26525384) (downloaded 09/11/
2013), HGMD Professional (HGMD Pro) v.2013,2 [3] (down-
loaded 06/26/2013), and SNPedia [27]. Gene annotations were
collected from OMIM [28] (downloaded 09/09/2013), disease-
gene associations were mined from the literature (http://diseases.
jensenlab.org downloaded 07/25/2013), and HGMD Pro
v.2013.2 [3]. NHGRI GWAS variants were included if they had
an odds-ratio (OR) or beta regression coefficient .1 and ,=20.
HGMD Pro variants were included if and only if they were in the
most confident disease mutation class (DM). SNPedia was used as
to identify SNPs associated with blood groups, known to be high
penetrance (http://snpedia.com/index.php?title=ABO_blood_
group&oldid=560223) [27]. Disease-gene associations mined from
literature were included only if they were rated as high confidence
by the mining algorithm. For associations from Jensen’s database
[29], which computes a Z-score for each disease-gene association,
we required Z-score .4.0 or ranking in the top-5 associated genes
for the disease, according to Z-score. HGMD Pro genes were
considered to be in the DM class if they contained at least one
mutation in the DM class. All HGMD Pro annotations used in the
models are included in Table S10. All GWAS annotations and
their allele frequencies are in Table S11.
Probabilistic model
We designed a Bayesian model to predict whether an individual
had a phenotype of interest, based on genome sequence and
estimated prevalence (Figure 5). Three categories of variable are
included in the model. Categorical variables (0, 1, or 2) in the first
layer represent observed genotypes, limited to those with
phenotype-associated variants and predicted functional variants.
Real-valued variables [0,1] in the second layer represent the
probability that phenotype-associated genes are functionally
altered. To estimate the aggregated penetrance of the genotypes,
functional alterations are grouped into four abstract categories in
the third layer. The probability that each of these categories is
altered depends either on high penetrance variants (Bernoulli
variable SVH); low penetrance variants (Bernoulli variable SVL);
high penetrance genes (Bernoulli variable SGH); or low penetrance
genes (Bernoulli variable SGL). The joint distribution of SVH, SVL,
SGH, SGL is used to infer the state of Bernoulli variable Y, which
represents phenotype status. (All equations and derivations are in
Text S1).
Model assessment
Each phenotypic model was assessed by its ability to correctly
rank individuals in the PGP cohort, as area under the ROC curve
(AUC). No cross-validation was performed because neither model
topology nor parameters were estimated or optimized with
information from the PGP cohort. P-values and FDR were
estimated with permutation. We applied two permutation tests. In
the first test, the identities of PGP participants were shuffled, and
in the second test, phenotype labels were shuffled. The first test
preserves correlation structure among phenotypes within each
participant. The second test assumes that phenotypes are
independent and exchangeable. (Mathematical details are in Text
S1).
Predicted functional impact on gene products
We used the Variant Effect Scoring Tool (VEST) [9] to score
the functional impact of variants and combined the VEST p-
values, using Fisher’s method, yielding a gene-level VEST statistic,
denoted as TGENE (Text S1: Eq. 2). We derived the probability
that the gene was functionally altered by all rare variants observed
in the individual, denoted as P(G=1|TGENE) using Bayes Rule
(Text S1: Eq. 24). All VEST scores and p-values are included in
Table S13.
Rank order matching of PGP participants and phenotypic
profiles in CAGI 2012–13
For each of the 77 PGP participants in the CAGI challenge, we
used their genome sequence as input to models for each of the 243
phenotypes included in the challenge, and the posterior probabil-
ity of each phenotype was computed. The match between each
PGP genome and phenotypic profile was modeled with a Bernoulli
A Probabilistic Model to Predict Clinical Traits from Genome Sequence
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likelihood, and the probability of each matched pair was
calculated. Profiles were ranked from most to least probable.
(Text S1)
Assessment of phenotype-genotype matching
algorithms in CAGI 2012–13
Prediction accuracy was measured by an independent assessor
with the following criteria. First, the number of correctly top-
ranked phenotypic profiles was computed. To assess the signifi-
cance of that finding, benchmark or null prediction used uniformly
random matches between phenotypic profiles and genomes, i.e.,
for a given genome, each phenotypic profile being equally
possible. The simulation was repeated 104 times and the number
of correctly top-ranked profiles was recorded each time. In this
setting, none of the simulations yielded five or more correctly top-
ranked phenotypic profiles to the corresponding genomes, and
hence the significance level for observing five or more correct
matches is ,1024.
Software to implement all methods is available from authors on
request.
Supporting Information
Figure S1 Prediction results of simple mutation burden
model. Six phenotypes predicted with AUC.0.7 are shown.
Each row represents a clinical phenotype and consists of 130 cells,
each of which represents a Personal Genome Project (PGP)
participant. Cells in each row are ranked by the burden of
putatively damaging alleles (MAF,0.01) in the same sets of
phenotype-associated genes used in Figure 1. Cell coloring has the
same meaning as in Figure 1. #PGP=number of participants in
each row having the true phenotypic status. AUC=area under the
receiver operating characteristic curve, a threshold-free metric of
classifier performance. p-value and FDR= statistical significance
of the AUC value, based on permutation testing.
(PDF)
Table S1 GWAS hits correctly identified that PGP-48
has Graves’ disease. A single PGP participant had Graves’
disease and she was ranked second out of 130, according to the
posterior probability of having this phenotype (AUC=1.0, P-
value = 0.01, FDR=0.039). Listed are the rsIDs of 16 GWAS hits,
the risk alleles harbored by PGP-48, and the zygosity of each
GWAS hit.
(XLSX)
Table S2 GWAS hits correctly identified that PGP-69
has alopecia areata. A single PGP participant had alopecia
areata, and he was ranked seventh out of 130, according to
posterior probability (AUC=0.953, P-value = 0.055,
FDR=0.143). Listed are the rsIDs of 7 GWAS hits, the risk
alleles harbored by PGP-69, and the zygosity of each GWAS hit.
(XLSX)
Table S3 GWAS hits correctly identified that PGP-39
has Crohn’s disease. A single PGP participant had Crohn’s
disease, and she was ranked ninth out of 130, according to
posterior probability (AUC=0.937, P-value = 0.072,
FDR=0.166). Listed are the rsIDs of 97 GWAS hits, the risk
alleles harbored by PGP-39, and the zygosity of each GWAS hit.
(XLSX)
Table S4 GWAS hits correctly identified that PGP-142
and PGP-72 have deep vein thrombosis. Two PGP
Figure 5. Topology of the model to predict phenotype from an individual’s genome sequence. Red nodes in the first layer of the model
represent the individual’s genotype calls at genomic positions associated with the phenotype of interest. They are sorted into three categories: VH
(HGMD DM variants), VL (NHGRI GWAS hits), and VF (,0.01 MAF in any population reported in ESP6500 (http://evs.gs.washington.edu/EVS/) or 1000
Genomes [30]), found in genes annotated as associated with the phenotype. Green nodes in the second layer represent genes split into high
penetrance GH or low penetrance GL based on database annotations. Blue nodes in the third layer are Bernoulli random variables, abstractly
representing mechanisms that explain the phenotype, sorted into those altered by high penetrance variants SVH, low penetrance variants SVL, high
penetrance genes SGH, or low penetrance genes SGL. The blue node Y is a Bernoulli random variable representing individual phenotypic status.
Directed edges show the dependencies between nodes. A set of model parameters is estimated for each phenotype and each individual.
doi:10.1371/journal.pcbi.1003825.g005
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participants had deep vein thrombosis, and they were ranked tenth
and twentieth out of 130, according to posterior probability
(AUC=0.893, P-value = 0.027, FDR=0.08). Listed are the rsIDs
of 9 GWAS hits, the risk alleles harbored by PGP-142 and PGP-
72, and the zygosity of each GWAS hit.
(XLSX)
Table S5 GWAS hits predicted that PGP-158 has aortic
aneurism. One PGP participant had aortic aneurism, and she
was ranked 34 out of 130, according to posterior probability
(AUC=0.76, P-value = 0.273, FDR=0.35). Listed are the rsIDs
of 2 GWAS hits, the risk alleles harbored by PGP-158, and the
zygosity of each GWAS hit.
(XLSX)
Table S6 GWAS hits correctly identified that PGP-39
and PGP-38 have chronic obstructive pulmonary disease
(COPD). Two PGP participants had COPD, and they were
ranked fifth and 56th out of 130, according to posterior probability
(AUC=0.772, P-value = 0.102, FDR=0.205). Listed are the
rsIDs of 6 GWAS hits, the risk alleles harbored by PGP-39 and
PGP-38, and the zygosity of each GWAS hit.
(XLSX)
Table S7 Phenotype model prediction performance
(AUC) for 130 PGP participants, using genome sequence
only, prevalence only, and both. Phenotypes are sorted by
the difference between AUC of the prevalence only model and the
AUC of the model that uses both genome sequence and
prevalence. Only phenotypes reported in at least one PGP are
listed.
(XLSX)
Table S8 Phenotypes that were predicted no better than
random by our models. Phenotype: the poorly predicted
clinical phenotypes. #PGP: the number of PGP participants who
reported having the phenotype. AUC: the area under the receiver
operating characteristic curve of our model predictions. p-value:
the statistical significance of each AUC. FDR: the false discovery
rate (FDR). None of the predictions are significant.
(XLSX)
Table S9 Prevalences for each phenotype used in this
work, based on age, gender, and ancestry when
available. Phenotypes are listed in column A. Columns B–H
list seven ancestral populations for which we were able to establish
phenotype population prevalence. For each ancestral population,
phenotype prevalence is listed for each combination of gender and
age range. Column I shows the source(s) of the data for the
phenotype.
(XLSX)
Table S10 Annotations of HGMD variants and genes.
Phenotypes are listed in column A. For variants, columns B–H list
genomic location, reference and risk alleles, PubMed identifiers,
and mutation consequence type. For genes, column B lists HUGO
identifier.
(XLSX)
Table S11 Annotations of GWAS hits. Phenotypes are listed
in column A. Columns B–H list genomic location, reference and
risk alleles, allele frequency, and reported effect size (odds ratio).
(XLSX)
Table S12 Phenotypes predicted with significant AUC
using a null model that assumes phenotypes are
independent and exchangeable. If no correlation structure
existed among the phenotypes, statistical significance could be
assessed by shuffling phenotype labels with respect to their
predicted probabilities. In this case, the model’s performance
declines slightly, yielding 21 phenotypes with P-value,0.05 and
FDR,0.2. #PGP=number of participants in each row having
the true phenotypic status. AUC=area under the receiver
operating characteristic curve, a threshold-free metric of classifier
performance. P-value and FDR= statistical significance of the
AUC value, based on permutation test shuffling the phenotype
labels.
(XLSX)
Table S13 Variant Effect Scoring Tool (VEST) scores. All
variants scored by VEST are shown. Columns A–L list genomic
location, strand, reference and alternative alleles, HUGO
identifiers, amino acid substitutions, VEST score, VEST p-value,
and MAF in European-American (EA), African-American (AA)
populations (from Exome Variant Server), and 1000 genomes
database where available.
(XLSX)
Text S1 Supplementary material.
(DOCX)
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